AIDX · 20/20 Biolabs, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-04-02 | Zhou Jiming |
Chief Operating Officer |
Award↑
|
Stock Option
|
150,000 |
| 2026-04-02 | Bergman Alan B. |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Direct)
25,000 of the shares subject to the stock option will vest on the first anniversary of the date of grant and the remaining shares will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service to the Issuer. |
Stock Option
|
100,000 |
| 2026-03-03 | Cohen Jonathan M |
Director, Chief Executive Officer, 10% Owner |
Award↑
Filing footnotes — Stock Option (Direct)
On March 3, 2026, the Reporting Person was granted a stock option for the purchase of 352,936 shares of common stock, which shall vest in equal quarterly installments over the following four (4) years, subject to the Reporting Person's continuous service to the Issuer. |
Stock Option
|
352,936 |
| 2026-02-19 | Ross Michael A. |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date. |
Common Stock
|
31 |
| 2026-02-19 | Ross Michael A. |
Director |
Other↓
Filing footnotes — Series A-2 Preferred Stock (Direct)
On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date. |
Series A-2 Preferred Stock
|
31 |
| 2026-02-19 | Rollins John Woodson |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date. |
Common Stock
|
13,029 |
| 2026-02-19 | Compton John G. |
Director |
Other↓
Filing footnotes — Series A-2 Preferred Stock (Direct)
On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date. |
Series A-2 Preferred Stock
|
7,669 |
| 2026-02-19 | COHEN RICHARD M |
Director |
Other↓
Filing footnotes — Series A-2 Preferred Stock (Direct)
On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date. |
Series A-2 Preferred Stock
|
7,700 |
| 2026-02-19 | COHEN RICHARD M |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date. |
Common Stock
|
7,700 |
| 2026-02-19 | Rollins John Woodson |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date. |
Common Stock
|
6,135 |
| 2026-02-19 | Rollins John Woodson |
Director |
Other↓
Filing footnotes — Series A-2 Preferred Stock (Direct)
On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date. |
Series A-2 Preferred Stock
|
6,135 |
| 2026-02-19 | Rollins John Woodson |
Director |
Other↓
Filing footnotes — Series A Preferred Stock (Direct)
On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date. |
Series A Preferred Stock
|
13,029 |
| 2026-02-19 | Compton John G. |
Director |
Other↑
Filing footnotes — Common Stock (Direct)
On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date. |
Common Stock
|
7,669 |
| 2026-02-17 | Bergman Alan B. |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |